RMCM
EDIT icon

Reynders McVeigh Capital Management’s Editas Medicine EDIT Stock Holding History

Reynders McVeigh Capital Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-5,650
Closed -$202K – 202
2018
Q2 		$202K Buy
+5,650
New +$200K 0.03% 200

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Reynders McVeigh Capital Management's EDIT Position: Q3 2018 in Review

Reynders McVeigh Capital Management sold out of Editas Medicine (EDIT) in Q3 2018, closing a stake of 5,650 shares — an estimated $202K sold.

Reynders McVeigh Capital Management first reported a position in EDIT in Q2 2018 and held it in 1 quarter. The position peaked at $202K in Q2 2018. 199 funds tracked by Wall St. Rank hold EDIT as of Q3 2018.

  • Reynders McVeigh Capital Management reported no remaining Editas Medicine position as of Q3 2018 after selling out during the quarter.
  • Reynders McVeigh Capital Management sold 5,650 Editas Medicine shares in Q3 2018, an estimated $202K.
  • Reynders McVeigh Capital Management first reported a position in Editas Medicine in Q2 2018 and held it in 1 quarter.
  • Reynders McVeigh Capital Management's Editas Medicine position peaked at $202K in Q2 2018.
  • 199 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2018.

Based on Reynders McVeigh Capital Management's 13F filing for Q3 2018, filed 20 Nov 2018.